All analyses
5 min read

Last updated:

Omega-3 and cognitive decline: a steady gap between cohorts and trials

Observational studies describe a reduction in dementia risk of about twenty percent. Randomized trials find a modest improvement limited to certain functions. Understanding this gap is better than picking the number that suits.

9 studies citedsee the sources

Benjamin Sant

Co-founder of the School of Longevity

Critical reading of scientific publications
Critical reading of scientific publications

Cohorts describe a strong association

A paper published in 2023 first used the Alzheimer's Disease Neuroimaging cohort, 1,135 participants without dementia, mean age 73, followed for six years. Long-term users of omega-3 supplements had a 64 percent lower risk of Alzheimer's disease, hazard ratio 0.36.

The authors then pooled 48 longitudinal studies totaling 103,651 participants. The level of evidence is rated moderate to high for a reduction of about 20 percent in the risk of all-cause dementia or cognitive decline, with an effect particularly associated with docosahexaenoic acid intake, relative risk 0.82 with heterogeneity of 63.6 percent.

The 64 percent figure must be handled with care. It comes from an observational analysis within a cohort, in people who choose to take supplements long term, and who differ in many other ways from those who do not. The measured effect encompasses those differences.

Randomized trials give much more modest results

A 2024 dose-response meta-analysis gathered 24 randomized trials, 9,660 participants aged 40 and over without dementia, with follow-ups of 3 to 36 months. The benefit concerns executive function, and it follows an upward trend during the first twelve months of intervention.

This benefit appears for a daily intake above 500 mg of omega-3 fatty acids, and up to 420 mg of eicosapentaenoic acid. It is more marked in regions where blood concentrations of docosahexaenoic acid and eicosapentaenoic acid are not very low, which is counterintuitive and worth pointing out.

An overview of systematic reviews published in 2025, nine reviews pooling 14 randomized trials and 26,881 participants aged 40 and over, finds a statistically significant but modest improvement in the mini-mental state examination score, effect size 0.16. An effect size of that order is not perceptible to the person concerned.

The gap between the two approaches is not a methodological detail

Twenty percent risk reduction in cohorts, an effect size of 0.16 on a cognitive score in trials: these two results do not measure the same thing, and that is the first explanation for the gap. The first concerns the incidence of a disease over years, the second a test score after a few months.

The second explanation is reverse causation and residual confounding. Someone who has eaten fatty fish regularly for decades generally has other habits, another socioeconomic level and another baseline health status. Statistical models correct part of these differences, never all of it.

The third is duration. A neurodegenerative process builds over fifteen to twenty years, and a twelve or twenty-four month trial in people already old comes late. It is the same problem encountered with most interventions tested against aging, where the effect seen in cohorts is not found in trials.

What the positive trials have in common

A 24-month double-blind randomized trial followed people aged 65 and over who were cognitively healthy, receiving daily 1 g of fish oil providing 430 mg of docosahexaenoic acid and 90 mg of eicosapentaenoic acid, combined with 22 mg of carotenoids and 15 mg of vitamin E, against placebo.

The active group made significantly fewer errors on working memory tasks, with effect sizes between 0.090 and 0.105. The gap widens as the cognitive load of the task increases, which is an interesting internal consistency argument.

Two characteristics recur in the trials that find something: a long duration, twelve to twenty-four months, and a dose of docosahexaenoic acid clearly higher than that of eicosapentaenoic acid. Short trials and formulations rich in eicosapentaenoic acid are overrepresented among neutral trials.

Why this article is rated Emerging and not Probable

The rating rests on three elements. Effect sizes in trials are small and measured on tests, not on clinical events. Heterogeneity between studies is high, 63.6 percent in the cohort meta-analysis. And no trial has demonstrated a reduction in dementia incidence.

An Emerging level does not mean useless. It means the results justify continuing to look, not building a firm recommendation. For someone who asks whether they should take omega-3 for their brain, the honest answer begins with this distinction.

It continues with a hierarchy. The levers whose effect on cognition is best established are not nutritional: physical activity, sleep, blood pressure control, corrected hearing. Offering a supplement before looking at these levers amounts to treating the subject at the margin.

How to discuss it, and the part that belongs to the physician

What can be said without being wrong: dietary intake of omega-3, especially docosahexaenoic acid, is associated in large cohorts with lower dementia risk, and supplementation trials find at best a modest improvement in executive function, from 500 mg a day and over at least twelve months.

What must not be said: that supplementation prevents Alzheimer's disease. No trial shows it, and the 64 percent figure circulating comes from an observational analysis in a cohort, not from a randomized trial.

Medical advice is required before any supplementation in a person on anticoagulants or antiplatelet agents, before planned surgery, and in case of known hemostasis disorder. For the rest, the dietary lever, two weekly portions of fish including one of fatty fish, remains the one best supported by the data, and it follows the same logic as the other supplements presented as anti-aging.

Sources

  1. 1.Wei BZ, et al. The Relationship of Omega-3 Fatty Acids with Dementia and Cognitive Decline: Evidence from Prospective Cohort Studies of Supplementation, Dietary Intake, and Blood Markers. Am J Clin Nutr. 2023.
  2. 2.Suh SW, et al. The influence of n-3 polyunsaturated fatty acids on cognitive function in individuals without dementia: a systematic review and dose-response meta-analysis. BMC Med. 2024.
  3. 3.Barros MI, et al. Omega-3 Polyunsaturated Fatty Acids and Cognitive Decline in Adults with Non-Dementia or Mild Cognitive Impairment: An Overview of Systematic Reviews. Nutrients. 2025.
  4. 4.Power R, et al. Omega-3 fatty acid, carotenoid and vitamin E supplementation improves working memory in older adults: A randomised clinical trial. Clin Nutr. 2022.
  5. 5.Calderon Martinez E, et al. The effects of omega-3, DHA, EPA, Souvenaid in Alzheimer's disease: A systematic review. Cureus. 2024.
  6. 6.Salman HB, et al. The effect of omega-3 fatty acid supplementation on weight loss and cognitive function in overweight or obese individuals on weight-loss diet. Nutr Hosp. 2022.
  7. 7.Wylenzek F, et al. A systematic review on the impact of nutrition and possible supplementation on the deficiency of vitamin complexes, iron, omega-3-fatty acids and zinc in women with heavy menstrual bleeding. Arch Gynecol Obstet. 2024.
  8. 8.Manson JE, et al. Principal results of the VITamin D and OmegA-3 TriaL (VITAL) and updated meta-analyses of relevant vitamin D trials. J Steroid Biochem Mol Biol. 2020.
  9. 9.Nevins JEH, et al. Omega-3 Fatty Acid Dietary Supplements Consumed During Pregnancy and Lactation and Child Neurodevelopment: A Systematic Review. J Nutr. 2021.

Reading studies is one thing, turning them into a plan is another

The Longevity Practitioner certification teaches the method that turns this kind of data into an accompaniment decision: assess, prioritise, plan over 90 days, re-measure, and know when to hand over.

See the certification

11 modules, €2,200. Enrol

Benjamin Sant

Co-founder of the School of Longevity

Cofounder of the School of Longevity with Tristan Maruyama. A former officer trained at Saint-Cyr from 2019 to 2022 and a coach since 2018, he has supported more than 4,000 people. He leads the School's editorial content with one constant principle: pass on only what can be situated, verified and applied seriously.

This article is published for information and education. It does not replace medical advice. For any personal health question, consult a healthcare professional.